NCT00483249 Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
| NCT ID | NCT00483249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Warren J. Gasper, MD |
| Condition | Thoracoabdominal Aortic Aneurysm |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2005-05 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2005-05 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a study to assess the safety and effectiveness of endovascular treatment of thoracoabdominal (TAAA) and paravisceral abdominal (PVAAA) aortic aneurysms. The investigational operation involves placing a stent-graft over the aortic aneurysm.
Eligibility Criteria
Inclusion Criteria 1. Aortic aneurysms: * greater than or equal to 6 cm in diameter in men, * greater than or equal to 5.5 cm in diameter in women, * and/or larger than 5 cm in diameter and enlarging at a rate of more than 5 mm/year, * and/or iliac aneurysms larger than 4 cm in diameter. 2. Anticipated mortality comparable to published rates with conventional surgical treatment. 3. Life expectancy more than 2 years. 4. Ability to give informed consent. 5. Willingness to comply with follow-up schedule. 6. Suitable arterial anatomy for endovascular repair. Exclusion Criteria 1. Free rupture of the aneurysm. 2. Pregnancy. 3. Known allergy to Nitinol, stainless steel, or polyester. 4. Unwillingness or inability to comply with the follow up schedule. 5. Serious systemic or groin infection. 6. Uncorrectable coagulopathy.
Contact & Investigator
Warren J Gasper, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT00483249 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracoabdominal Aortic Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00483249 currently recruiting?
Yes, NCT00483249 is actively recruiting participants. Contact the research team at warren.gasper@ucsf.edu for enrollment information.
Where is the NCT00483249 trial being conducted?
This trial is being conducted at San Francisco, United States, San Francisco, United States.
Who is sponsoring the NCT00483249 clinical trial?
NCT00483249 is sponsored by Warren J. Gasper, MD. The principal investigator is Warren J Gasper, MD at University of California, San Francisco. The trial plans to enroll 250 participants.